flu_vaccination_grippe_5115654021_3

Five Chinese coronavirus vaccines in overseas clinical trials

pharmafile | November 19, 2020 | News story | Business Services  

Five different coronavirus vaccines from China are being tested in Phase 3 trials around the world. 

The countries conducting the trials are the UAE, Brazil, Pakistan and Peru. Two of the vaccines are being developed by the China National Pharmaceutical Group (Sinopharm); one inactivated vaccine is being developed by Sinovac; one adenoviral vector vaccine is being developed in collaboration between the Academy of Military Sciences and CanSino; and the final on is a recombinant protein vaccine developed by Anhui Zhifei Longcom Biologic Pharmacy. 

Foreign Ministry Spokesperson Zhao Lijian said: “After the pandemic broke out, the Chinese Government at the earliest time possible laid out five technical routes including inactivated vaccine, recombinant protein vaccine, adenoviral vector vaccine, attenuated influenza vaccine and nucleic acid vaccine.”

China is also closely cooperating with the World Health Organization on vaccines. The country joined the WHO-sponsored COVID-19 Tools Accelerator initiative and the Solidarity trial for treatments, as well as COVAX to promote fair distribution of vaccines. Zhao also said: “We hope Chinese vaccines will be included in COVAX’s procurement list as soon as possible after their development, which will contribute to the accessibility and affordability of vaccines in developing countries.”

Yesterday, Sinovac reported that its vaccine showed success in mid-stage clinical trials after his candidate led to a quick immune response during trials that assessed around 700 people.

Conor Kavanagh

Related Content

No items found

Latest content